Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemia.

Abstract

Takeda Pharmaceutical Co Ltd is developing TAK-475, a squalene synthetase inhibitor from a series of 4,1-benzoxazepine-3-acetic acid derivatives, for the potential oral treatment of hyperlipidemia. By March 2005, TAK-475 was undergoing phase III clinical trials in the US and Europe.

• Authors: John R Burnett
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 7 Issue 9 Pg. 850-6 (Sep 2006) ISSN: 1472-4472 [Print] England
• PMID: 17002264 (Publication Type: Journal Article, Review)

Chemical References

• 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid
• Enzyme Inhibitors
• Hypolipidemic Agents
• Oxazepines
• Piperidines
• Farnesyl-Diphosphate Farnesyltransferase

Topics

• Animals
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Enzyme Inhibitors (pharmacology, therapeutic use)
• Farnesyl-Diphosphate Farnesyltransferase (antagonists & inhibitors)
• Humans
• Hypolipidemic Agents (adverse effects, pharmacokinetics, pharmacology, toxicity)
• Oxazepines (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
• Piperidines (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
• Quantitative Structure-Activity Relationship